{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123369","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.550970+00:00","generated_at":"2026-05-30T03:28:09.312436+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Adaptive Biotechnologies Q3 revenue $46.4M (+22%); MRD revenue up 52%; net loss narrows to $32.1M","bullets":["Revenue $46.4M (+22% YoY); MRD revenue $37.5M (+52%); Immune Medicine $9.0M (-32%).","Net loss $32.1M vs $50.3M YoY; Adjusted EBITDA loss $14.3M vs $29.8M.","clonoSEQ test volume 19,600 (+30%); Medicare gapfill rate raised 17% to $2,007/test.","MRD revenue guidance raised to $143-145M (prev. $140-145M); op. expense guidance cut to $335-340M.","Cash, cash equivalents and marketable securities $267.2M; interest expense on revenue interest purchase $2.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123369","json":"https://secwatch.observer/filing/0000950170-24-123369.json","markdown":"https://secwatch.observer/filing/0000950170-24-123369.md","text":"https://secwatch.observer/filing/0000950170-24-123369.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024123369/0000950170-24-123369-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024123369/adpt-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:28:09.312436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}